Treatment of restless legs syndrome

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 4, 2009, Pages

  Ferini Strambi, Luigi ^a   Manconi, Mauro ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Augmentation; Dopamine receptor agonists; Restless legs syndrome

Indexed keywords

ANTICONVULSIVE AGENT; ASCORBIC ACID; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CABERGOLINE; CARBAMAZEPINE; CLONAZEPAM; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; FERRIC HYDROXIDE SUCROSE; FERROUS SULFATE; GABAPENTIN; HYDROCORTISONE; IRON DERIVATIVE; LEVODOPA; LISURIDE; LORAZEPAM; NIMETAZEPAM; OPIATE DERIVATIVE; OXYCODONE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; TEMAZEPAM; UNINDEXED DRUG; VALPROIC ACID;

AEROBIC EXERCISE; ARTICLE; ASIAN; BEDTIME DOSAGE; BEHAVIOR DISORDER; BINDING AFFINITY; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE COURSE; DIZZINESS; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG WITHDRAWAL; EASTERN EUROPE; EVENING DOSAGE; EVIDENCE BASED MEDICINE; FATIGUE; HUMAN; IRON DEFICIENCY; LOW DRUG DOSE; LUNG FIBROSIS; MOTOR DYSFUNCTION; NAUSEA; ORTHOSTATIC HYPOTENSION; PATHOLOGICAL GAMBLING; POLYSOMNOGRAPHY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; RETROPERITONEAL FIBROSIS; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SKIN MANIFESTATION; SOMNOLENCE; SYMPTOM; TREATMENT DURATION; VOMITING; WALKING; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

DOPAMINE AGONISTS; HUMANS; LEVODOPA; RESTLESS LEGS SYNDROME; TREATMENT OUTCOME;

EID: 72649089380     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70838-7     Document Type: Article

References (56)

1. American Academy of Sleep Medicine. International Classification of Sleep Disorders. Diagnostic and Coding Manual (2005), American Academy of Sleep Medicine, Westchester, IL
2. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., Montplaisi J., et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institute of Health. Sleep Med 4 (2003) 101-119
3. Montplaisir J., Allen R., Walters A., and Ferini-Strambi L. Restless legs syndrome and periodic limb movements during sleep. In: Kryger M.H., Roth T., and Dement W.C. (Eds). Principles and Practice of Sleep Medicine. 4th ed. (2005), Elsevier, Philadelphia 839-852
4. Michaud M., Dumont M., Selmaoui B., Paquet J., Fantini M.L., and Montplaisir J. Circadian rhythm of restless legs syndrome symptoms: relationship with biological markers. Ann Neurol 55 (2004) 372-380
5. Qu S., Le W., Zhang X., Xie W., Zhang A., and Ondo W.G. Locomotion is increased in a11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome. J Neuropathol Exp Neurol 66 (2007) 383-388
6. Dean Jr. T., Allen R.P., O'Donnell C.P., and Earley C.J. The effects of dietary iron deprivation on murine circadian sleep architecture. Sleep Med 7 (2006) 634-640
7. Allen R.P., and Earley C.J. The role of iron in restless legs syndrome. Mov Disord 22 Suppl 18 (2007) S440-S448
8. Coleman R.M. Periodic movements in sleep (nocturnal myoclonus) and restless legs syndrome. In: Guilleminault C. (Ed). Sleeping and waking disorders: indications and techniques (1982), Addison-Wesley, Menlo Park, CA 265-295
9. Trenkwalder C., Högl B., and Winkelmann J. Recent advances in the diagnosis, genetics and treatment of restless legs syndrome. J Neurol 256 (2009) 539-553
10. Allen R.P., Walters A.S., Montplaisir J., Hening W., Myers A., Bell T.J., et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 165 (2005) 1286-1292
11. Winkelmann J., Schormair B., Lichtner P., Ripke S., Xiong L., Jalilzadeh S., et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 39 (2007) 1000-1006
12. Stefansson H., Rye D.B., Hicks A., Petursson H., Ingason A., Thorgeirsson T.E., et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 357 (2007) 639-647
13. Gemignani F., and Brindani F. Restless legs syndrome associated with peripheral neuropathy. Eur J Neurol 14 (2007) e9-e10
14. Merlino G., Fratticci L., Valente M., Del Giudice A., Noacco C., Dolso P., et al. Association of restless legs syndrome in type 2 diabetes: a case-control study. Sleep 30 (2007) 866-871
15. Italian REMS Study Group, Manconi M., Ferini-Strambi L., Filippi M., Bonanni E., Iudice A., et al. Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep 31 (2008) 944-952
16. Rottach K.G., Schaner B.M., Kirch M.H., Zivotofsky A.Z., Teufel L.M., Gallwitz T., et al. Restless legs syndrome as a side effect of second generation antidepressants. J Psychiatr Res 43 (2008) 70-75
17. Oertel W.H., Trenkwalder C., Zucconi M., Benes H., Borreguero D.G., Bassetti C., et al. State of the art in restless legs syndrome: practice recommendations for treating restless legs syndrome. Mov Disord 22 Suppl 18 (2007) S466-S475
18. Aukerman M.M., Aukerman D., Bayard M., Tudiver F., Thorp L., and Bailey B. Exercise and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med 19 (2006) 487-493
19. Hornyak M., Grossmann C., Kohnen R., Schlatterer M., Richter H., Voderholzer U., et al. Cognitive behavioural group therapy to improve patients' strategies for coping with restless legs syndrome: a proof-of-concept trial. J Neurol Neurosurg Psychiatry 79 (2008) 823-825
20. Trenkwalder C., Hening W.A., Montagna P., Oertel W.H., Allen R.P., Walters A.S., et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 23 (2008) 2267-2302
21. Stiasny-Kolster K., Kohnen R., Möller J.C., Trenkwalder C., and Oertel W.H. Validation of the "L-DOPA test" for diagnosis of restless legs syndrome. Mov Disord 21 (2006) 1333-1339
22. Vignatelli L., Billiard M., Clarenbach P., Garcia-Borreguero D., Kaynak D., Liesiene V., et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 13 (2006) 1049-1065
23. García-Borreguero D., Kohnen R., Högl B., Ferini-Strambi L., Hadjigeorgiou G.M., Hornyak M., et al. Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 8 (2007) 455-463
24. Stiasny-Kolster K., Benes H., Peglau I., Hornyak M., Holinka B., Wessel K., et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 63 (2004) 2272-2279
25. Zucconi M., Oldani A., Castronovo V., and Ferini-Strambi L. Cabergoline is an effective single-drug treatment for restless legs syndrome: clinical and actigraphic evaluation. Sleep 26 (2003) 815-818
26. Zanetti R., Antonini A., Gatto G., Gentile R., Tesei S., and Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356 (2007) 39-46
27. Schade R., Andersohn F., Suissa S., Haverkamp W., and Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356 (2007) 29-38
28. Danoff S.K., Grasso M.E., Terry P.B., and Flynn J.A. Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest 120 (2001) 313-316
29. Worthington A., and Thomas L. Valvular heart disease associated with taking lowdose pergolide for restless legs syndrome. Eur J Echocardiogr 9 (2008) 828-830
30. Montplaisir J., Nicolas A., Denesle R., et al. Pramipexole alleviates sensory and motor symptoms of restless legs syndrome. Neurology 52 (1998) 938-943
31. Oertel W.H., Stiasny-Kolster K., Bergtholdt B., Hallström Y., Albo J., Leissner L., et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 22 (2007) 213-219
32. Allen R., Becker P.M., Bogan R., Schmidt M., Kushida C.A., Fry J.M., et al. Ropinirole decreases periodic limb movements and improves sleep parameters in patients with restless legs syndrome. Sleep 27 (2004) 907-914
33. Garcia-Borreguero D., Grunstein R., Sridhar G., Dreykluft T., Montagna P., Dom R., et al. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med 8 (2007) 742-752
34. Quilici S., Abrams K.R., Nicolas A., Martin M., Petit C., Lleu P.L., et al. Metaanalysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med 9 (2008) 715-726
35. Manconi M., Ferri R., Zucconi M., Oldani A., Fantini M.L., Castronovo V., et al. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements. Sleep Med 8 (2007) 491-497
36. Saletu B., Gruber G., Saletu M., Brandstätter N., Hauer C., Prause W., et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 41 (2000) 181-189
37. Möller C., Körner Y., Cassel W., Meindorfner C., Krüger H.P., Oertel W.H., et al. Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome. Sleep Med 7 (2006) 333-339
38. Evans A.H., and Butzkueven H. Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Mov Disord 22 (2007) 590-591
39. Quickfall J., and Suchowersky O. Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord 13 (2007) 535-536
40. Tippmann-Peikert M., Park J.G., Boeve B.F., Shepard J.W., and Silber M.H. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 68 (2007) 301-303
41. Evans A.H., and Stegeman J.R. Punding in patients on dopamine agonists for restless leg syndrome. Mov Disord 24 (2009) 140-141
42. Stiasny-Kolster K., Kohnen R., Schollmayer E., Möller J.C., Oertel W.H., and Rotigotine Sp 666 Study Group. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 19 (2004) 1432-1438
43. Oertel W.H., Benes H., Garcia-Borreguero D., Geisler P., Högl B., Saletu B., et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 9 (2008) 228-239
44. Trenkwalder C., Benes H., Poewe W., Oertel W.H., Garcia-Borreguero D., de Weerd A.W., et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 7 (2008) 595-604
45. Earley C.J., and Allen R.P. Restless legs syndrome augmentation associated with tramadol. Sleep Med 7 (2006) 592-593
46. Happe S., Sauter C., Klösch G., Saletu B., and Zeitlhofer J. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology 48 (2003) 82-86
47. Hornyak M., Rupp A., Riemann D., Feige B., Berger M., and Voderholzer U. Low-dose hydrocortisone in the evening modulates symptom severity in restless legs syndrome. Neurology 70 (2008) 1620-1622
48. Earley C.J., Horská A., Mohamed M.A., Barker P.B., Beard J.L., and Allen R.P. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med 10 (2009) 206-211
49. Grote L., Leissner L., Hedner J., and Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord 24 (2009) 1445-1452
50. Enomoto M., Inoue Y., Namba K., Munezawa T., and Matsuura M. Clinical characteristics of restless legs syndrome in end-stage renal failure and idiopathic RLS patients. Mov Disord 23 (2008) 811-816
51. Molnar M.Z., Novak M., Ambrus C., Szeifert L., Kovacs A., Pap J., et al. Restless Legs Syndrome in patients after renal transplantation. Am J Kidney Dis 45 (2005) 388-396
52. Manconi M., Govoni V., De Vito A., Economou N.T., Cesnik E., Casetta I., et al. Restless legs syndrome and pregnancy. Neurology 63 (2004) 1065-1069
53. Sommer M., Bachmann C.G., Liebetanz K.M., Schindehütte J., Tings T., and Paulus W. Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol Scand 115 (2007) 347-350
54. Winkelman J.W., Finn L., and Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med 7 (2006) 545-552
55. Pennestri M.H., Montplaisir J., Colombo R., Lavigne G., and Lanfranchi P.A. Nocturnal blood pressure changes in patients with restless legs syndrome. Neurology 68 (2007) 1213-1218
56. Winkelman J.W., Shahar E., Sharief I., and Gottlieb D.J. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology 70 (2008) 35-42